Quality Disconnect

News
Article
Pharmaceutical TechnologyPharmaceutical Technology-01-02-2008
Volume 32
Issue 1

QbD, PAT, design space, what's it all about? This seems to be a common industry response to FDA's directional push.

Welcome to Pharmaceutical Technology's new PharmTech Talk column. In the year ahead, our editors will be discussing what we hear you discussing such as the statement above. We all attend conferences and workshops, and we all sit quietly and nod our heads as we listen to experts and regulators tell us what we're supposed to be doing to meet standards. But during much-needed coffee breaks, predinner cocktails, and networking receptions, real views tend to come out. It's in those "off-the-record" chats that we hear what you really think about "the state of the industry."

Angie Drakulich

Take the 2007 American Association of Pharmaceutical Scientists meeting. Despite the numerous, jam-packed quality-by-design and process analytical technology sesssions, I kept hearing disgruntlement from attendees: "Why do we have to change our entire system if FDA is not changing the way it does inspections?" "If we provide FDA with more detailed information, that will open the door to more questions—and perhaps less approvals." "I agree with QbD, but the higher-ups won't pay for it until there are proven results (i.e., revenue)." "Quality systems and harmonization are not required—so why follow them?"

Another common concern had to do with the global impact on the pharma industry. If a company finalizes its design space, for example, and then decides to contract out a few steps, different regulations in different countries throw a wrench in the whole based, risk managment" plan.

We'd like to hear your thoughts on these issues, so please email adrakulich@advanstar.com Stay tuned for more PharmTech Talks. Angie Drakulich is the managing editor of Pharmaceutical Technology.

A few readers commented on this column. Click here to read their thoughts.

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Related Content